Avior Bio Inc.



March 08,2021
Avior Completes a Convertible Debt Financing with Pacific Premier Trust
January 27,2021
Avior-Bio receives $250,000 Strategic Business Loan from North Carolina Biotechnology Center.


October 28, 2020
Holly Springs startup targets ‘intractable and persistent’ itch often linked to liver cancer

October 20, 2020

Avior Bio Announces Positive Results with AV104 Buccal Film in First-in-Human Phase 1 Study.

 July 23, 2020

Avior Bio Receives Authorization to Initiate First-in-Human Phase 1 Pharmacokinetics, Safety and Tolerability Study with AV104 Buccal Films

 April 2, 2020

Avior Demonstrates Rapid Buccal Absorption within 10 minutes of Nalmefene Using Speedit™ Film Technology platform as a Medical Countermeasure for the Reversal of Opioid-Induced Respiratory Depression in a Beagle Dog Model  


December 12, 2019
Avior Demonstrates Significantly Superior Bioavailability of AV103 films as Compared to Commercial Selincro® in a Beagle Dog Model

September 19, 2019

Sono-Tek Enters Into Agreement With Avior Bio Inc


July 22, 2019 
Avior files PCT Patent Application for its Speedit™ formulation and method of manufacturing.


July 12, 2019
Avior Signs Clinical Manufacturing Deal with Protoform Inc.

March 8, 2019

National Institute of Health Awards Avior’s First Phase 1 SBIR Grant – “A Novel Fast Acting Nalmefene Film for the Treatment of Opioid Overdose”

January 3, 2019
Avior establishes a developmental laboratory at the Biolabs’ Innovation Center in downtown, Durham, NC.  


November 24, 2018
Avior signs a strategy small-business research loan with North Carolina Biotechnology Center.

October 25, 2018
Avior files Patent Application – 870/3 PROV titled – Method and Device of Treating Chronic Kidney Disease associated Pruritus.

September 14, 2018
Avior develops its first prototype formulation using Speedit™ transmucosal delivery

May 02, 2018

Avior and Quality Chemical Laboratories (QCL) Enter Partnership a $1 Million Investment     

April 12, 2018

Avior Demonstrates that AV104 Significantly Suppresses Substance P Induced Pruritus in a Well Established C57BL Rodent Pharmacodynamic Model

Feb 22, 2018
Avior files for Incorporation in the State of North Carolina